These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29134945)

  • 1. Drug-drug interaction potential of the HBV and HDV entry inhibitor myrcludex B assessed in vitro.
    Blank A; Meier K; Urban S; Haefeli WE; Weiss J
    Antivir Ther; 2018; 23(3):267-275. PubMed ID: 29134945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP.
    Donkers JM; Zehnder B; van Westen GJP; Kwakkenbos MJ; IJzerman AP; Oude Elferink RPJ; Beuers U; Urban S; van de Graaf SFJ
    Sci Rep; 2017 Nov; 7(1):15307. PubMed ID: 29127322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effects of NTCP-inhibitor myrcludex B.
    Cheng D; Han B; Zhang W; Wu W
    J Viral Hepat; 2021 Jun; 28(6):852-858. PubMed ID: 33599010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.
    Lütgehetmann M; Mancke LV; Volz T; Helbig M; Allweiss L; Bornscheuer T; Pollok JM; Lohse AW; Petersen J; Urban S; Dandri M
    Hepatology; 2012 Mar; 55(3):685-94. PubMed ID: 22031488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.
    Bogomolov P; Alexandrov A; Voronkova N; Macievich M; Kokina K; Petrachenkova M; Lehr T; Lempp FA; Wedemeyer H; Haag M; Schwab M; Haefeli WE; Blank A; Urban S
    J Hepatol; 2016 Sep; 65(3):490-8. PubMed ID: 27132170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.
    Volz T; Allweiss L; Ben MBarek M; Warlich M; Lohse AW; Pollok JM; Alexandrov A; Urban S; Petersen J; Lütgehetmann M; Dandri M
    J Hepatol; 2013 May; 58(5):861-7. PubMed ID: 23246506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.
    Nkongolo S; Ni Y; Lempp FA; Kaufman C; Lindner T; Esser-Nobis K; Lohmann V; Mier W; Mehrle S; Urban S
    J Hepatol; 2014 Apr; 60(4):723-31. PubMed ID: 24295872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro.
    Weiss J; Haefeli WE
    Int J Antimicrob Agents; 2013 May; 41(5):484-7. PubMed ID: 23428312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
    Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
    Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions.
    Weiss J; Bajraktari-Sylejmani G; Haefeli WE
    Chem Biol Interact; 2021 Apr; 338():109428. PubMed ID: 33647240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro.
    Weiss J; Becker JP; Haefeli WE
    Int J Antimicrob Agents; 2014 Feb; 43(2):184-8. PubMed ID: 24332840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging concepts for the treatment of hepatitis delta.
    Elazar M; Glenn JS
    Curr Opin Virol; 2017 Jun; 24():55-59. PubMed ID: 28475945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.
    Jeong HU; Kwon M; Lee Y; Yoo JS; Shin DH; Song IS; Lee HS
    Drug Des Devel Ther; 2015; 9():643-53. PubMed ID: 25653502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis D Virus Entry Inhibitors Based on Repurposing Intestinal Bile Acid Reabsorption Inhibitors.
    Kirstgen M; Lowjaga KAAT; Müller SF; Goldmann N; Lehmann F; Glebe D; Baringhaus KH; Geyer J
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33921515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections.
    Tu T; Urban S
    Curr Opin Virol; 2018 Jun; 30():68-79. PubMed ID: 29775812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Transporters Involved in Beraprost Sodium Transport In Vitro.
    Oshida K; Shimamura M; Seya K; Ando A; Miyamoto Y
    Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):117-128. PubMed ID: 26961540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Novel HBV/HDV Entry Inhibitors by Pharmacophore- and QSAR-Guided Virtual Screening.
    Kirstgen M; Müller SF; Lowjaga KAAT; Goldmann N; Lehmann F; Alakurtti S; Yli-Kauhaluoma J; Baringhaus KH; Krieg R; Glebe D; Geyer J
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bona fide receptor for hepatitis B and D viral infections: Mechanism, research models and molecular drug targets.
    Yu Y; Li S; Liang W
    Emerg Microbes Infect; 2018 Jul; 7(1):134. PubMed ID: 30050063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients.
    Loglio A; Ferenci P; Uceda Renteria SC; Tham CYL; van Bömmel F; Borghi M; Holzmann H; Perbellini R; Trombetta E; Giovanelli S; Greco L; Porretti L; Prati D; Ceriotti F; Lunghi G; Bertoletti A; Lampertico P
    J Hepatol; 2019 Oct; 71(4):834-839. PubMed ID: 31302176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of hepatitis delta: Need for novel therapeutic options.
    Abbas Z; Abbas M
    World J Gastroenterol; 2015 Aug; 21(32):9461-5. PubMed ID: 26327754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.